Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™

Citius Pharmaceuticals reported its first revenue of $3.9 million in Q1 2026 following the December 2025 launch of LYMPHIR by its majority-owned subsidiary Citius Oncology. The drug, approved for treating relapsed or refractory cutaneous T-cell lymphoma, has begun initial sales through a nationwide distributor network. The company raised $20.9 million in equity financing and is advancing late-stage pipeline candidates Mino-Lok and Halo-Lido while exploring international expansion and combination therapy opportunities.

02/13/2026, 8:00 AM • Benzinga

Citius Oncology, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™

Citius Oncology reported its first revenue of $3.9 million following the successful December 2025 U.S. commercial launch of LYMPHIR, an FDA-approved immunotherapy for cutaneous T-cell lymphoma. The company established nationwide distribution infrastructure and deployed an AI-enabled commercial platform. Despite positive commercial progress, the company reported a net loss of $5.5 million for Q1 2026 and held $7.3 million in cash as of December 31, 2025.

02/13/2026, 8:00 AM • Benzinga

Stock Market Today: Dow Jones, Nasdaq Futures Slip On Christmas Eve Despite Strong Q3 GDP Report— UiPath, AST SpaceMobile, Ramaco In Focus (UPDATED)

U.S. stock futures declined slightly on Christmas Eve despite a strong Q3 GDP report showing 4.3% annualized growth. Major indices ended higher on Tuesday, with communication services, IT, and energy stocks leading gains. Several stocks gained attention: UiPath jumped 7% after joining the S&P Midcap 400, Citius Pharmaceuticals rose 8.65% on better-than-expected earnings, Ramaco Resources gained 8% after announcing a $100M buyback, and Multi Ways Holdings surged 62.86% on strong revenue growth.

12/24/2025, 9:04 AM • Benzinga

Stock Market Today: Dow Jones, S&P 500 Futures Drop On Christmas Eve Despite Strong Q3 GDP Report—UiPath, AST SpaceMobile, Ramaco Resources In Focus

U.S. stock futures declined on Christmas Eve despite a strong Q3 GDP report showing 4.3% annualized growth. The S&P 500 and Nasdaq 100 ETFs fell slightly in premarket trading. Notable gainers included UiPath (joining S&P Midcap 400), Citius Pharmaceuticals (beat earnings), Ramaco Resources (announced $100M buyback), AST SpaceMobile, and Multi Ways Holdings (strong revenue growth). Markets close early at 1 p.m. ET today and remain closed Thursday.

12/24/2025, 5:32 AM • Benzinga

Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules

Citius Oncology closed a registered direct offering and private placement, raising approximately $18 million to support the commercial launch of LYMPHIR and for general corporate purposes.

12/10/2025, 4:30 PM • Benzinga

Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules

Citius Oncology raised $18 million through a registered direct offering and private placement to support the commercial launch of LYMPHIR, a novel cancer immunotherapy for cutaneous T-cell lymphoma, with H.C. Wainwright & Co. acting as the exclusive placement agent.

12/09/2025, 8:30 AM • Benzinga

Citius Oncology Announces Closing of $9.0 Million Registered Direct Offering and Concurrent Private Placement

Citius Oncology closed a $9.0 million registered direct offering and private placement, issuing 5,142,858 shares of common stock and accompanying warrants at $1.75 per share, with warrants exercisable at $1.84 per share.

09/10/2025, 4:30 PM • Benzinga

Citius Oncology Announces Pricing of $9.0 Million Registered Direct Offering and Concurrent Private Placement

Citius Oncology has entered a securities purchase agreement to sell 5,142,858 shares of common stock at $1.75 per share, with concurrent warrants, expected to raise approximately $9.0 million.

09/09/2025, 8:30 AM • Benzinga

Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update

Citius Pharmaceuticals reported its Q3 2025 financial results, highlighting $12.5 million in gross financings and preparations for LYMPHIR's U.S. launch in Q4 2025. The company experienced a reduced net loss compared to the previous year and continues to advance its oncology and critical care product pipeline.

08/12/2025, 4:30 PM • Benzinga

Citius Oncology, Inc. Reports Fiscal Third Quarter 2025 Financial Results and Provides Business Update

Citius Oncology reported its Q3 2025 financial results, highlighting preparations for the commercial launch of LYMPHIR, a therapy for cutaneous T-cell lymphoma, with $12.5 million raised to support pre-launch initiatives.

08/12/2025, 4:30 PM • Benzinga

Citius Oncology Announces Pricing of $9.0 Million Public Offering

Citius Oncology priced a public offering of 6,818,182 shares and warrants at $1.32 per share, expecting to raise approximately $9.0 million to support LYMPHIR commercialization and general corporate purposes.

07/16/2025, 9:15 AM • Benzinga